REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, announced its participation in three upcoming virtual investor conferences. These include the SVB Leerink CybeRx Series on October 1, 2020, the Jefferies Virtual Gene Therapy/Editing Summit on October 2, 2020, and the Chardan Virtual 4th Annual Genetic Medicines Conference on October 6, 2020, featuring a fireside chat at 10:30 a.m. ET. Investors can access a live webcast and a 30-day archived replay on the company's website.

ROCKVILLE, Md., Sept. 25, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced it will participate in the following upcoming investor conferences, which will each be held in a virtual meeting format:

SVB Leerink CybeRx Series: Rare Diseases & Genetic Medicines
Date: Thursday, October 1, 2020

Jefferies Virtual Gene Therapy/Editing Summit
Date: Friday, October 2, 2020

Chardan Virtual 4^th Annual Genetic Medicines Conference
Date: Tuesday, October 6, 2020
Fireside Chat: Tuesday, October 6, 2020 at 10:30 a.m. ET

A live webcast of the Chardan fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the fireside chat webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

View original content:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301138006.html

SOURCE REGENXBIO Inc.

FAQ

What are the dates for REGENXBIO's upcoming investor conferences?

REGENXBIO will participate in three conferences: SVB Leerink CybeRx Series on October 1, 2020, Jefferies Virtual Gene Therapy/Editing Summit on October 2, 2020, and Chardan Virtual 4th Annual Genetic Medicines Conference on October 6, 2020.

How can I access the live webcast for the Chardan fireside chat?

The live webcast for the Chardan fireside chat can be accessed in the Investors section of REGENXBIO's website.

What is REGENXBIO focused on in the biotechnology sector?

REGENXBIO is focused on improving lives through gene therapy, utilizing its proprietary NAV Technology Platform.

What is the significance of the NAV Technology Platform for REGENXBIO?

The NAV Technology Platform consists of exclusive rights to over 100 novel AAV vectors, essential for developing gene therapy candidates in various therapeutic areas.

Where can I find more information about REGENXBIO's upcoming events?

More information about REGENXBIO's upcoming events can be found on their official website.